Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909487 | 0.76 | BACE1 (0.40) | BACE1KDM4EALDH1A1GLAGAA | |
| SCHEMBL31605956 | 0.76 | BACE1 (0.40) | BACE1KDM4EALDH1A1GLAGAA | |
| SCHEMBL30578403 | 0.75 | TSHR (0.39) | RPS6KA5KDM4EHPGDHSD17B10RPS6KA4 | |
| SCHEMBL31500927 | 0.73 | CDC7 (0.37) | RPS6KA5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16244139 | 0.72 | RPS6KA5 (0.47) | RPS6KA5KDM4EALDH1A1GLAGAA | |
| SCHEMBL27604587 | 0.70 | BACE1 (0.43) | BACE1KDM4EALDH1A1GLAGAA | |
| SCHEMBL29449203 | 0.68 | PTPN1 (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL839531 | 0.68 | PTPN1 (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL29965863 | 0.64 | KDM4E (0.55) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1417158 | 0.64 | KDM4E (0.55) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-04 | — | — | US | claimed |
| EP-3368034-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | Children's Hospital Medical Center (US) | 2018-09-05 | — | — | EP | claimed |
| US-9855273-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-02 | — | — | US | claimed |
| EP-2999470-B1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2017075054-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-05-04 | — | — | WO | claimed |
| US-20170087162-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-03-30 | — | — | US | claimed |
| US-9504706-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-11-29 | — | — | US | claimed |
| EP-2999470-A2 | COMBINATION THERAPY FOR MDS | Children's Hospital Medical Center (US) | 2016-03-30 | — | — | EP | claimed |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-02-11 | — | — | US | claimed |
| US-9168257-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2015-10-27 | — | — | US | claimed |
| WO-2014190163-A2 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-11-27 | — | — | WO | claimed |
| US-20140350070-A1 | Combination Therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2014-11-27 | — | — | US | claimed |
| US-20210292843-A1 | TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED IRAK | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-23 | — | — | US | disclosed |
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-04 | — | — | US | disclosed |
| EP-3368034-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | Children's Hospital Medical Center (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9855273-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-02-11 | — | — | US | disclosed |
| US-9168257-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2014190163-A2 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140350070-A1 | Combination Therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087162-A1 | COMBINATION THERAPY FOR MDS | MCL1, IRAK4, IRAK3 | BACE1 4163/4885RPS6KA5 1023/4885KDM4E 745/4885 |
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | IRAK1, IRAK4, IRAK2 | BACE1 3922/4885RPS6KA5 641/4885KDM4E 2239/4885 |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | MCL1, IRAK4, IRAK3 | BACE1 4163/4885RPS6KA5 1023/4885KDM4E 745/4885 |
| US-20140350070-A1 | Combination Therapy for MDS | MCL1, IRAK4, IRAK3 | BACE1 4163/4885RPS6KA5 1023/4885KDM4E 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.